AstraZeneca's COPD drug scores two late-stage trial wins as full data boosts blockbuster hopes
The full data reinforces hopes that the drug could be a breakthrough COPD treatment and reach AstraZeneca's peak annual sales forecast of more than $5 billion.
The full data reinforces hopes that the drug could be a breakthrough COPD treatment and reach AstraZeneca's peak annual sales forecast of more than $5 billion. This story matters for Finance & Markets readers tracking bond. Reported by cnbc.com. Read the full original at the source link below.
Originally reported by cnbc.com. BondNews.com curates and briefs the finance & markets stories that matter. Our editorial policy →
Get the daily bond signal